Introduction: It is a known fact that dyslipidemia subsist in psychiatric patients on both typical and atypical antipsychotics mono-therapy. Could these regimens in combination be favorable against dyslipidemia? This study therefore investigated the effect of chlorpromazine and haloperidol combination on the lipid profile of schizophrenic patients. Methodology: The test comprised 26 patients among which 16 go well with the criteria of study. Chlorpromazine 200mg nocte in combination with haloperidol starting at 15 __ampersandsignndash; 20mg daily in divided doses were administered. Blood samples were collected prior to experiment (basal level) and six weeks (final level) later for lipid profile evaluation and levels compared to those of control (n=30), who were apparently healthy non psychiatric patients. Results: Compared to control, patients showed increased BMI and blood pressure. Lipid profile was significantly different (basal levels) prior to the experiment. Final lipid profile showed significant increase (P__ampersandsignlt;0.05) in TG, TC, LDLc and VLDLc and significantly decreased (P__ampersandsignlt;0.05) HDLc compared to basal levels and control. Atherogenic indices (TC/HDL and LDL/HDL) of patients were significantly higher (P__ampersandsignlt;0.05) and this effect was potentiated with six weeks of chlorpromazine/haloperidol combination therapy. Conclusion: The observed changes suggest lipid disorders in schizophrenic patients which was exacerbated with chlorpromazine/haloperidol combination therapy.